Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Autoimmune Disorders

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 488 articles:
HTML format



Single Articles


    April 2021
  1. LAMBE J, Risher H, Filippatou AG, Murphy OC, et al
    Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
    Neurology. 2021 Apr 7. pii: WNL.0000000000011933.
    PubMed     Abstract available


  2. BOURDETTE D, Killestein J
    Quelling Public Fears about Guillain-Barre Syndrome and COVID-19 Vaccination.
    Neurology. 2021 Apr 6. pii: WNL.0000000000011882.
    PubMed    


  3. MARQUEZ LOZA AM, Holroyd KB, Johnson SA, Pilgrim DM, et al
    Guillain- Barre Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial: Temporal Associations Do Not Imply Causality.
    Neurology. 2021 Apr 6. pii: WNL.0000000000011881.
    PubMed    


  4. ALLEN JA, Pasnoor M, Dimachkie MM, Ajroud-Driss S, et al
    Quantifying Treatment-Related Fluctuations in CIDP: Results of the GRIPPER Study.
    Neurology. 2021;96:e1876-e1886.
    PubMed     Abstract available


    March 2021
  5. POIRION E, Tonietto M, Lejeune FX, Ricigliano VAG, et al
    Structural and Clinical Correlates of a Periventricular Gradient of Neuroinflammation in Multiple Sclerosis.
    Neurology. 2021 Mar 18. pii: WNL.0000000000011700.
    PubMed     Abstract available


  6. GARDIN T, Longbrake EE
    Inducing or "Unmasking" Autoimmunity? The Role of Immune Checkpoint Therapy in Propagating Neurologic Immune-Related Adverse Events.
    Neurology. 2021 Mar 16. pii: WNL.0000000000011812.
    PubMed    


  7. LAMBE J, Fitzgerald KC, Murphy OC, Filippatou AG, et al
    Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis.
    Neurology. 2021 Mar 2. pii: WNL.0000000000011788.
    PubMed     Abstract available


  8. VILLOSLADA P, Galetta SL, Toosy A
    Seeing the Finish Line: Can Baseline OCT Values Predict Long-Term Disability and Therapeutic Management in Multiple Sclerosis?
    Neurology. 2021 Mar 2. pii: WNL.0000000000011793.
    PubMed    


  9. BANSAL P, Paul BS, Singh G
    Multiple Sclerosis Relapse Presenting As Sensorineural Hearing Loss.
    Neurology. 2021 Mar 2. pii: WNL.0000000000011796.
    PubMed    


    February 2021
  10. MUTHUSAMY K, Boyer S, Patterson M, Bierau J, et al
    Neuroimaging Findings in Inosine Triphosphate Pyrophosphohydrolase (ITPase) Deficiency.
    Neurology. 2021 Feb 16. pii: WNL.0000000000011719.
    PubMed    


  11. KALAITZIDIS G, Calabresi PA
    Is Cerebrospinal Fluid Responsible for Innate Immune Cell Activation and Neurotoxicity in Multiple Sclerosis?
    Neurology. 2021 Feb 15. pii: WNL.0000000000011694.
    PubMed    



  12. Evaluation of Multiple Sclerosis Disability Outcome Measures Using Pooled Clinical Trial Data.
    Neurology. 2021 Feb 12. pii: WNL.0000000000011677.
    PubMed    


  13. SOLE G, Mathis S, Friedman D, Salort-Campana E, et al
    Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis.
    Neurology. 2021 Feb 10. pii: WNL.0000000000011669.
    PubMed     Abstract available


  14. ZEPHIR H, Poupart J, Deschamps R, Audoin B, et al
    Author Response: Evaluation of Efficacy and Tolerability of First-Line Therapies in NMOSD.
    Neurology. 2021;96:295-296.
    PubMed    


  15. LEITE MI
    Reader Response: Evaluation of Efficacy and Tolerability of First-Line Therapies in NMOSD.
    Neurology. 2021;96:294-295.
    PubMed    


  16. DALAKAS MC
    Limited Benefits Halt Enrollment in Hematopoietic Stem Cell Transplantation Trial for Stiff-Person Syndrome: Should There Be More to Come?
    Neurology. 2021;96:239-240.
    PubMed    


  17. BURT RK, Balabanov R, Han X, Quigley K, et al
    Autologous Hematopoietic Stem Cell Transplantation for Stiff-Person Spectrum Disorder: A Clinical Trial.
    Neurology. 2021;96:e817-e830.
    PubMed     Abstract available


  18. RIM J, Byler M, Soldatos A, Notarangelo L, et al
    Opinion and Special Articles: Cerebellar Ataxia and Liver Failure Complicating IPEX Syndrome.
    Neurology. 2021;96:e956-e959.
    PubMed    


  19. VALLAT JM, Duchesne M, Corcia P, Richard L, et al
    The Wide Spectrum of Pathophysiologic Mechanisms of Paraproteinemic Neuropathy.
    Neurology. 2021;96:214-225.
    PubMed     Abstract available


  20. NISHI R, Koike H, Ohyama K, Fukami Y, et al
    Association Between IL-5 Levels and the Clinicopathologic Features of Eosinophilic Granulomatosis With Polyangiitis.
    Neurology. 2021;96:226-229.
    PubMed    


    January 2021
  21. ALPING P, Burman J, Lycke J, Frisell T, et al
    Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Non-induction Therapies for Multiple Sclerosis.
    Neurology. 2021 Jan 29. pii: WNL.0000000000011545.
    PubMed     Abstract available


  22. BROWNLEE WJ, Galetta S
    Optic Nerve in Multiple Sclerosis Diagnostic Criteria: An Aye to the Eyes?
    Neurology. 2021;96:139-140.
    PubMed    


  23. SORMANI MP, Tur C, Barkhof F
    Ibudilast: A Paradigm Shift for Progressive Multiple Sclerosis?
    Neurology. 2021;96:141-142.
    PubMed    


  24. SPAGNI G, Tricoli L, Modoni A, Monforte M, et al
    Clinical Reasoning: A 71-Year-Old Man Presenting With Acute Onset Dysarthria and Dysphagia.
    Neurology. 2021;96:180-184.
    PubMed    


  25. BOFFA G, Massacesi L, Inglese M, Mariottini A, et al
    Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
    Neurology. 2021 Jan 20. pii: WNL.0000000000011461.
    PubMed     Abstract available


  26. LEAVITT VM, Rocca M
    Siponimod for Cognition in Secondary Progressive Multiple Sclerosis: Thinking Through the Evidence.
    Neurology. 2021;96:91-92.
    PubMed    


  27. ROCCA MA, Valsasina P, Meani A, Gobbi C, et al
    Association of Gray Matter Atrophy Patterns with Clinical Phenotype and Progression in Multiple Sclerosis.
    Neurology. 2021 Jan 13. pii: WNL.0000000000011494.
    PubMed     Abstract available


  28. PAPP V, Magyari M, Aktas O, Berger T, et al
    Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review.
    Neurology. 2021;96:59-77.
    PubMed     Abstract available


  29. GREEN C, Morrison H, Smith P, Golestani F, et al
    Teaching Neuroimages: COVID-19-Associated Acute Disseminated Encephalomyelitis With Corpus Callosal Hemorrhage.
    Neurology. 2021;96:e307-e308.
    PubMed    


  30. BOVIS F, Kalincik T, Lublin F, Cutter G, et al
    Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.
    Neurology. 2021;96:e214-e227.
    PubMed     Abstract available


  31. SHAH S, Klassen BT, Flanagan EP
    Paroxysmal Dysarthria-Ataxia in Multiple Sclerosis.
    Neurology. 2021 Jan 5. pii: WNL.0000000000011498.
    PubMed    


  32. KALINCIK T, Sormani MP, Tur C
    Has the Time Come to Revisit Our Standard Measures of Disability Progression in Multiple Sclerosis?
    Neurology. 2021;96:12-13.
    PubMed    


    December 2020
  33. KALINCIK T, Diouf I, Sharmin S, Malpas C, et al
    Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
    Neurology. 2020 Dec 28. pii: WNL.0000000000011242.
    PubMed     Abstract available



  34. The 2013 clinical course descriptors for multiple sclerosis: A clarification.
    Neurology. 2020 Dec 22. pii: WNL.0000000000011198.
    PubMed    


  35. BENEDICT RHB, Tomic D, Cree BA, Fox R, et al
    Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses.
    Neurology. 2020 Dec 16. pii: WNL.0000000000011275.
    PubMed     Abstract available


  36. VIDAL-JORDANA A, Rovira A, Arrambide G, Otero-Romero S, et al
    Optic nerve region in multiple sclerosis diagnosis: the utility of visual evoked potentials.
    Neurology. 2020 Dec 16. pii: WNL.0000000000011339.
    PubMed     Abstract available


  37. LEVISON LS, Thomsen RW, Sindrup SH, Andersen H, et al
    Association of Hospital-Diagnosed Infections and Antibiotic Use with Risk of Developing Guillain-Barre Syndrome.
    Neurology. 2020 Dec 14. pii: WNL.0000000000011342.
    PubMed     Abstract available


  38. GRAUS F, Dalmau J
    Author response: Hashimoto encephalopathy in the 21st century.
    Neurology. 2020;95:1068.
    PubMed    


  39. SHUBHAKARAN K
    Reader response: Hashimoto encephalopathy in the 21st century.
    Neurology. 2020;95:1067-1068.
    PubMed    


  40. LEE MY, Yong KP, Hyun JW, Kim SH, et al
    Incidence of interattack asymptomatic brain lesions in NMO spectrum disorder.
    Neurology. 2020;95:e3124-e3128.
    PubMed     Abstract available


  41. RUSS JB, Timbie CM, Li Y, Gonzalez-Giraldo E, et al
    Clinical Reasoning: An 11-year-old girl with focal seizures, fevers, and unilateral, enhancing cortical lesions.
    Neurology. 2020;95:e3153-e3159.
    PubMed    


  42. TANBOON J, Inoue M, Hirakawa S, Tachimori H, et al
    Pathological features of anti-Mi-2 dermatomyositis.
    Neurology. 2020 Dec 4. pii: WNL.0000000000011269.
    PubMed     Abstract available


  43. NISHIJIMA H, Suzuki C, Kon T, Nakamura T, et al
    Bilateral Thalamic Lesions Associated with Atezolizumab-induced Autoimmune Encephalitis.
    Neurology. 2020 Dec 2. pii: WNL.0000000000011297.
    PubMed    


  44. NAISMITH RT, Bermel RA, Coffey CS, Goodman AD, et al
    Effects of ibudilast on MRI measures in the phase 2 SPRINT-MS study.
    Neurology. 2020 Dec 2. pii: WNL.0000000000011314.
    PubMed     Abstract available


  45. LANGESKOV-CHRISTENSEN M, Grondahl Hvid L, Nygaard MKE, Ringgaard S, et al
    Efficacy of high-intensity aerobic exercise on brain MRI measures in multiple sclerosis.
    Neurology. 2020 Dec 1. pii: WNL.0000000000011241.
    PubMed     Abstract available


  46. BINZER S, Manouchehrinia A, Hillert J
    Author response: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
    Neurology. 2020;95:1026.
    PubMed    


  47. BSTEH G, Berger T
    Reader response: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
    Neurology. 2020;95:1025-1026.
    PubMed    


  48. GANESH A, Galetta S
    Editors' note: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
    Neurology. 2020;95:1025.
    PubMed    


  49. SPATOLA M, Petit Pedrol M, Maudes E, Simabukuro M, et al
    Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis.
    Neurology. 2020;95:e3012-e3025.
    PubMed     Abstract available


    November 2020
  50. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
    Cancer incidence and mortality rates in multiple sclerosis: A matched cohort study.
    Neurology. 2020 Nov 25. pii: WNL.0000000000011219.
    PubMed     Abstract available


  51. LI V, Malladi P, Simeoni S, Pakzad M, et al
    A clinico-neurophysiological study of urogenital dysfunction in MOG-antibody transverse myelitis.
    Neurology. 2020;95:e2924-e2934.
    PubMed     Abstract available


  52. MANTEGAZZA R, Wolfe GI, Muppidi S, Wiendl H, et al
    Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension.
    Neurology. 2020 Nov 23. pii: WNL.0000000000011207.
    PubMed     Abstract available


  53. BRIL V, Benatar M, Andersen H, Vissing J, et al
    Efficacy and safety of rozanolixizumab in moderate-to-severe generalised myasthenia gravis: A phase 2 RCT.
    Neurology. 2020 Nov 20. pii: WNL.0000000000011108.
    PubMed     Abstract available


  54. FEIBEL RM
    Henry R. Viets, MD, and the history of myasthenia gravis.
    Neurology. 2020 Nov 20. pii: WNL.0000000000011239.
    PubMed     Abstract available


  55. NARAYANASWAMI P, Sanders DB, Wolfe G, Benatar M, et al
    International consensus guidance for management of myasthenia gravis: 2020 update.
    Neurology. 2020 Nov 3. pii: WNL.0000000000011124.
    PubMed     Abstract available


  56. HOANG P, Hurtubise B, Muppidi S
    Clinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection.
    Neurology. 2020;95:840-843.
    PubMed    


    October 2020
  57. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    Reliability of outcome measures in clinical trials in secondary progressive multiple sclerosis.
    Neurology. 2020 Oct 26. pii: WNL.0000000000011123.
    PubMed     Abstract available


  58. KLEIN DA COSTA B, Brant de Souza Melo R, Passos GRD, Gomes Meneses Sevilha Castro D, et al
    Unraveling B lymphocytes in CNS inflammatory diseases: Distinct mechanisms and treatment targets.
    Neurology. 2020;95:733-744.
    PubMed     Abstract available


  59. MASTRANGELO V, Asioli GM, Foschi M, Padroni M, et al
    Bilateral extensive corticospinal tract lesions in MOG antibody-associated disease.
    Neurology. 2020;95:648-649.
    PubMed    


  60. FELIPE-RUCIAN A, Wegener-Panzer A, Nassenstein I, Reindl M, et al
    Teaching NeuroImages: Bilateral optic neuritis: When to suspect anti-MOG antibodies.
    Neurology. 2020;95:e2045-e2046.
    PubMed    


    September 2020
  61. RINGELSTEIN M, Harmel J, Zimmermann H, Brandt AU, et al
    Author response: Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders.
    Neurology. 2020;95:610.
    PubMed    


  62. CHEN JJ
    Reader response: Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders.
    Neurology. 2020;95:609-610.
    PubMed    


  63. GIANNOCCARO MP, Paolucci M, Zenesini C, Di Stasi V, et al
    Comparison of ice pack test and single-fiber EMG diagnostic accuracy in patients referred for myasthenic ptosis.
    Neurology. 2020;95:e1800-e1806.
    PubMed     Abstract available



  64. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
    Neurology. 2020 Sep 16. pii: WNL.0000000000008927.
    PubMed    


  65. MOCCIA M, van de Pavert S, Eshaghi A, Haider L, et al
    Pathological correlates of the magnetization transfer ratio in multiple sclerosis.
    Neurology. 2020 Sep 16. pii: WNL.0000000000010909.
    PubMed     Abstract available


  66. SHELLY S, Paul P, Bi H, Dubey D, et al
    Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm.
    Neurology. 2020 Sep 16. pii: WNL.0000000000010910.
    PubMed     Abstract available


  67. ROTSTEIN DL, Yeh EA
    Could wider social networks prevent disability in MS and other neurologic disorders?
    Neurology. 2020;95:463-464.
    PubMed    


  68. LIBERATORE G, De Santis T, Doneddu PE, Gentile F, et al
    Clinical Reasoning: A case of COVID-19 associated pharyngeal-cervical-brachial variant of Guillain-Barre syndrome.
    Neurology. 2020 Sep 11. pii: WNL.0000000000010817.
    PubMed    


  69. KULICK-SOPER CV, McKee JL, Wolf RL, Mohan S, et al
    Pearls & Oy-sters: Bilateral globus pallidus lesions in a patient with COVID-19.
    Neurology. 2020;95:454-457.
    PubMed    


  70. VIRHAMMAR J, Kumlien E, Fallmar D, Frithiof R, et al
    Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid.
    Neurology. 2020;95:445-449.
    PubMed     Abstract available


  71. BENITO-LEON J, Mendez-Guerrero A, Gutierrez-Ortiz C
    Author response: Miller Fisher syndrome and polyneuritis cranialis in COVID-19.
    Neurology. 2020;95:409.
    PubMed    


  72. NI J, Xu X
    Reader response: Miller Fisher syndrome and polyneuritis cranialis in COVID-19.
    Neurology. 2020;95:408-409.
    PubMed    


  73. SIEGLER JE 3RD, Galetta S
    Editors' note: Miller Fisher syndrome and polyneuritis cranialis in COVID-19.
    Neurology. 2020;95:408.
    PubMed    


  74. SEESE RR, Guillen D, Gaesser JM, Abdel-Hamid HZ, et al
    Clinical Reasoning: A 14-year-old boy with acute weakness, paresthesias, and headache.
    Neurology. 2020;95:e1285-e1289.
    PubMed    


  75. KWON YN, Jung JH, Kim SJ, Sung JJ, et al
    Progressive brain atrophy and white matter changes in MOG encephalomyelitis.
    Neurology. 2020;95:402-403.
    PubMed    


    August 2020
  76. BENITO-LEON J, Mendez-Guerrero A, Gutierrez-Ortiz C
    Author response: Miller Fisher syndrome and polyneuritis cranialis in COVID-19.
    Neurology. 2020;95:370.
    PubMed    


  77. VAVOUGIOS GD
    Reader response: Miller Fisher syndrome and polyneuritis cranialis in COVID-19.
    Neurology. 2020;95:369.
    PubMed    


  78. VAIRA LA, Salzano G, De Riu G
    Reader response: Miller Fisher syndrome and polyneuritis cranialis in COVID-19.
    Neurology. 2020;95:368-369.
    PubMed    


  79. LEWIS A, Galetta S
    Editors' note: Miller Fisher syndrome and polyneuritis cranialis in COVID-19.
    Neurology. 2020;95:368.
    PubMed    


  80. WALLIN MT
    Initial highly effective therapy for MS: A strong start.
    Neurology. 2020;95:e1114-e1116.
    PubMed    


  81. SECHI E, Markovic SN, McKeon A, Dubey D, et al
    Neurological autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.
    Neurology. 2020 Aug 13. pii: WNL.0000000000010632.
    PubMed     Abstract available


  82. DOUGHTY CT, Guidon AC
    Stronger together: Diagnostic testing for ocular myasthenia gravis.
    Neurology. 2020 Aug 11. pii: WNL.0000000000010616.
    PubMed    


  83. RUPRECHT K, Pfuhl C, Oechtering J
    Author response: Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis.
    Neurology. 2020;95:277-278.
    PubMed    


  84. ALCALA C, Perez-Miralles FC, Gil-Perotin S, Casanova B, et al
    Reader response: Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis.
    Neurology. 2020;95:277.
    PubMed    


  85. SIEGLER JE 3RD, Galetta S
    Editors' note: Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis.
    Neurology. 2020;95:276.
    PubMed    


  86. OUTTERYCK O, Lopes R, Drumez E, Labreuche J, et al
    Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome.
    Neurology. 2020;95:e733-e744.
    PubMed     Abstract available


  87. VAN KEMPEN ZLE, Hoogervorst ELJ, Wattjes MP, Kalkers NF, et al
    Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
    Neurology. 2020;95:e745-e754.
    PubMed     Abstract available


  88. DIXON L, Shah S
    Teaching NeuroImages: Hypertrophic polyneuropathy.
    Neurology. 2020;95:e779-e780.
    PubMed    


  89. LEE I, Kuo HC, Aban IB, Cutter GR, et al
    Minimal manifestation status and prednisone withdrawal in the MGTX trial.
    Neurology. 2020;95:e755-e766.
    PubMed     Abstract available


  90. ARINO H, Munoz-Lopetegi A, Martinez-Hernandez E, Armangue T, et al
    Sleep disorders in anti-NMDAR encephalitis.
    Neurology. 2020;95:e671-e684.
    PubMed     Abstract available


  91. LEVIN SN, Riley CS, Dhand A, White CC, et al
    Association of Social Network Structure and Physical Function in Patients With Multiple Sclerosis.
    Neurology. 2020 Aug 7. pii: WNL.0000000000010460.
    PubMed     Abstract available


  92. MENDOZA M, Tran C, Bril V, Katzberg HD, et al
    Patient-acceptable symptom states in myasthenia gravis.
    Neurology. 2020 Aug 5. pii: WNL.0000000000010574.
    PubMed     Abstract available


  93. PIEHL F, Wolfe GI
    Is the treatment of myasthenia gravis improving? Why not ask our patients?
    Neurology. 2020 Aug 5. pii: WNL.0000000000010578.
    PubMed    


  94. DINKIN M, Gao V, Kahan J, Bobker S, et al
    COVID-19 presenting with ophthalmoparesis from cranial nerve palsy.
    Neurology. 2020;95:221-223.
    PubMed    


  95. GUTIERREZ-ORTIZ C, Mendez-Guerrero A, Rodrigo-Rey S, San Pedro-Murillo E, et al
    Miller Fisher syndrome and polyneuritis cranialis in COVID-19.
    Neurology. 2020;95:e601-e605.
    PubMed     Abstract available


  96. NELSON LM, Bourdette D
    Two decades of research: Time to incorporate comorbidity management into the care of MS?
    Neurology. 2020;95:193-194.
    PubMed    


  97. SALTER A, Kowalec K, Fitzgerald KC, Cutter G, et al
    Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.
    Neurology. 2020;95:e446-e456.
    PubMed     Abstract available


  98. BOSE G, Fitzpatrick T, Yogendrakumar V, Zwicker JC, et al
    Clinical Reasoning: A 73-year-old man with recurrent aphasia, headaches and confusion.
    Neurology. 2020 Aug 4. pii: WNL.0000000000010475.
    PubMed    


    July 2020
  99. KILLESTEIN J, Du Pasquier R, Hemmer B
    Vaccination in B-cell depleted MS patients.
    Neurology. 2020 Jul 29. pii: WNL.0000000000010378.
    PubMed    


  100. BAR-OR A, Calkwood JC, Chognot C, Evershed J, et al
    Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
    Neurology. 2020 Jul 29. pii: WNL.0000000000010380.
    PubMed     Abstract available


  101. VILLOSLADA P, Sanchez-Dalmau B, Galetta S
    Optical coherence tomography: A useful tool for identifying subclinical optic neuropathy in diagnosing multiple sclerosis.
    Neurology. 2020 Jul 28. pii: WNL.0000000000009840.
    PubMed    


  102. HAUSER SL, Kappos L, Arnold DL, Bar-Or A, et al
    Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
    Neurology. 2020 Jul 20. pii: WNL.0000000000010376.
    PubMed     Abstract available


  103. SANTORO JD, Waltz M, Aaen G, Belman A, et al
    Pediatric Multiple Sclerosis Severity Score in a Large U.S. Cohort.
    Neurology. 2020 Jul 20. pii: WNL.0000000000010414.
    PubMed     Abstract available


  104. KAPOOR R, Smith KE, Allegretta M, Arnold DL, et al
    Serum neurofilament light as a biomarker in progressive multiple sclerosis.
    Neurology. 2020 Jul 16. pii: WNL.0000000000010346.
    PubMed     Abstract available


  105. HERRAETS IJT, Goedee HS, Telleman JA, van Eijk RPA, et al
    Nerve ultrasound for diagnosing chronic inflammatory neuropathy: a multicenter validation study.
    Neurology. 2020 Jul 16. pii: WNL.0000000000010369.
    PubMed     Abstract available


  106. HERMAN C, Mayer K, Sarwal A
    Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19.
    Neurology. 2020;95:77-84.
    PubMed     Abstract available


  107. CHEN JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, et al
    Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder.
    Neurology. 2020;95:e111-e120.
    PubMed     Abstract available


  108. MANISCALCO GT, Mariotto S, Hoftberger R, Capra R, et al
    GABAA receptor autoimmunity after alemtuzumab treatment for multiple sclerosis.
    Neurology. 2020 Jul 10. pii: WNL.0000000000010310.
    PubMed    


  109. GIOVANNONI G, Knappertz V, Steinerman JR, Tansy AP, et al
    A randomized, placebo-controlled phase 2 trial of laquinimod in primary progressive multiple sclerosis.
    Neurology. 2020 Jul 10. pii: WNL.0000000000010284.
    PubMed     Abstract available


  110. FERREIRA D, Ferro D, Bastos G, Pinto M, et al
    Teaching NeuroImages: Useless (and restless) hand of Oppenheim in multiple sclerosis.
    Neurology. 2020 Jul 9. pii: WNL.0000000000010261.
    PubMed    


  111. TOMSCHIK M, Hilger E, Rath J, Mayer EM, et al
    Subgroup Stratification and Outcome in Recently Diagnosed Generalized Myasthenia Gravis.
    Neurology. 2020 Jul 8. pii: WNL.0000000000010209.
    PubMed     Abstract available


  112. BURON MD, Chalmer TA, Sellebjerg F, Barzinji I, et al
    Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
    Neurology. 2020 Jul 7. pii: WNL.0000000000010135.
    PubMed     Abstract available


    June 2020
  113. PONCIANO A, Carvalho JN, Gala D, Leite J, et al
    Pearls & Oy-sters: Guillain-Barre syndrome: An unusual presentation of acute intermittent porphyria.
    Neurology. 2020 Jun 19. pii: WNL.0000000000009838.
    PubMed    


  114. RUITER AM, Naber WC, Tannemaat MR, Verschuuren JJGM, et al
    The face of myasthenia gravis.
    Neurology. 2020 Jun 10. pii: WNL.0000000000009782.
    PubMed    


  115. JONSSON DI, Sveinsson O, Hakim R, Brundin L, et al
    Author response: Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study.
    Neurology. 2020;94:1049-1050.
    PubMed    


  116. PAPP V, Petersen T, Magyari M, Koch-Henriksen N, et al
    Reader response: Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study.
    Neurology. 2020;94:1048-1049.
    PubMed    


  117. VAN KEMPEN ZLE, Kryscio RJ, Dalla Costa G
    Serum neurofilament light as a prognostic marker for MS disability: Are we there yet?
    Neurology. 2020;94:1013-1014.
    PubMed    


  118. DAVION JB, Lopes R, Drumez E, Labreuche J, et al
    Asymptomatic optic nerve lesions: An underestimated cause of silent retinal atrophy in MS.
    Neurology. 2020;94:e2468-e2478.
    PubMed     Abstract available


  119. BIRCA V, Saint-Martin C, Myers KA
    Teaching Video NeuroImages: Pathologic yawning: A sign of brainstem involvement in acute disseminated encephalomyelitis?
    Neurology. 2020;94:e2497-e2498.
    PubMed    


  120. COSTELLO F, Dalakas MC
    Cranial Neuropathies and COVID-19: Neurotropism and Autoimmunity.
    Neurology. 2020 Jun 2. pii: WNL.0000000000009921.
    PubMed     Abstract available


  121. ALLENBACH Y, Uzunhan Y, Toquet S, Leroux G, et al
    Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases.
    Neurology. 2020 Jun 2. pii: WNL.0000000000009727.
    PubMed     Abstract available


  122. GUIDON AC, Amato AA
    COVID-19 and neuromuscular disorders.
    Neurology. 2020;94:959-969.
    PubMed     Abstract available


  123. MARRIE RA, Leavitt VM
    Disease-modifying therapies as cognition-modifying therapies? Treating cognitive impairment in MS.
    Neurology. 2020;94:957-958.
    PubMed    


  124. MARTINEZ-HERNANDEZ E, Guasp M, Garcia-Serra A, Maudes E, et al
    Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies.
    Neurology. 2020;94:e2302-e2310.
    PubMed     Abstract available


  125. CORREALE J, Marrodan M, Benarroch EE
    What is the role of axonal ion channels in multiple sclerosis?
    Neurology. 2020 Jun 1. pii: WNL.0000000000009754.
    PubMed    


    May 2020
  126. LUBLIN FD, Coetzee T, Cohen JA, Marrie RA, et al
    The 2013 clinical course descriptors for multiple sclerosis: A clarification.
    Neurology. 2020 May 29. pii: WNL.0000000000009636.
    PubMed     Abstract available


  127. RAFAY MF, Shapiro KA, Surmava AM, deVeber GA, et al
    Spectrum of cerebral arteriopathies in children with arterial ischemic stroke.
    Neurology. 2020 May 26. pii: WNL.0000000000009557.
    PubMed     Abstract available


  128. MANOUCHEHRINIA A, Stridh P, Khademi M, Leppert D, et al
    Plasma neurofilament light levels are associated with the risk of disability in multiple sclerosis.
    Neurology. 2020 May 20. pii: WNL.0000000000009571.
    PubMed     Abstract available


  129. LANDMEYER NC, Burkner PC, Wiendl H, Ruck T, et al
    Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.
    Neurology. 2020 May 19. pii: WNL.0000000000009522.
    PubMed     Abstract available


  130. LAMBE J, Rothman A, Prince J, Saidha S, et al
    Retinal pathology occurs in stiff-person syndrome.
    Neurology. 2020;94:e2126-e2131.
    PubMed     Abstract available


  131. DALE RC, Rostasy K
    Autoimmune pediatric neuropsychiatric symptoms with pain and hypertension: CASPR2 antibody.
    Neurology. 2020 May 18. pii: WNL.0000000000009521.
    PubMed    


  132. SYRBE S, Stettner GM, Bally J, Borggraefe I, et al
    CASPR2 autoimmunity in children expanding to mild encephalopathy with hypertension.
    Neurology. 2020 May 18. pii: WNL.0000000000009523.
    PubMed     Abstract available


  133. MATHIS S, Soulages A, Le Masson G, Vallat JM, et al
    History of acute polyradiculoneuropathy (part 2): From 1916 to 2019.
    Neurology. 2020;94:836-840.
    PubMed     Abstract available


  134. VAN OMMEREN R, Izenberg A, Shadowitz S, Aviv R, et al
    Clinical Reasoning: An 81-year-old woman with decreased consciousness and fluctuating right facial droop.
    Neurology. 2020;94:843-848.
    PubMed    


  135. CORTESE M, Munger KL, Martinez-Lapiscina EH, Barro C, et al
    Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
    Neurology. 2020;94:e1950-e1960.
    PubMed     Abstract available


  136. GADOT R, Nascimento FA, Mims M, Nunez-Wallace K, et al
    Clinical Reasoning: A 59-year-old woman with multiple myeloma and lower extremity weakness and numbness.
    Neurology. 2020;94:794-800.
    PubMed    


    April 2020
  137. ARUN T, Pattison L, Palace J
    Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysis: A retrospective cohort study.
    Neurology. 2020 Apr 30. pii: WNL.0000000000009491.
    PubMed     Abstract available


  138. MATHIS S, Soulages A, Vallat JM, Le Masson G, et al
    History of acute polyradiculoneuropathy (part 1): The prehistory of Guillain-Barre syndrome.
    Neurology. 2020 Apr 28. pii: WNL.0000000000009401.
    PubMed     Abstract available


  139. KIM HW, Lamb C, Jamali S, Lopez Chiriboga AS, et al
    Mystery Case: Anti-NMDAR encephalitis with overlapping demyelinating syndrome.
    Neurology. 2020;94:e1866-e1869.
    PubMed    


  140. NISHI R, Koike H, Ohyama K, Fukami Y, et al
    Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA.
    Neurology. 2020;94:e1726-e1737.
    PubMed     Abstract available


  141. POUPART J, Giovannelli J, Deschamps R, Audoin B, et al
    Evaluation of efficacy and tolerability of first-line therapies in NMOSD.
    Neurology. 2020;94:e1645-e1656.
    PubMed     Abstract available


  142. HUSSEIN O, Jordan Z, Abd Elazim A, Stino A, et al
    Pearls & Oy-sters: Rapid progression of prion disease associated with transverse myelitis: A rare presentation.
    Neurology. 2020;94:e1670-e1672.
    PubMed    


  143. LANGER-GOULD A, Smith JB, Albers KB, Xiang AH, et al
    Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort.
    Neurology. 2020 Apr 13. pii: WNL.0000000000009374.
    PubMed     Abstract available


  144. DOBSON R, Mowry EM
    Breastfeeding may reduce postpartum relapse in some women with multiple sclerosis.
    Neurology. 2020 Apr 13. pii: WNL.0000000000009369.
    PubMed    


  145. MEALY MA, Kozachik SL, Cook LJ, Totonis L, et al
    Scrambler therapy improves pain in neuromyelitis optica: A randomized controlled trial.
    Neurology. 2020 Apr 8. pii: WNL.0000000000009370.
    PubMed     Abstract available


  146. LEAVITT VM
    Neurologic determinism? Key update to an age-old debate.
    Neurology. 2020;94:605-606.
    PubMed    


  147. BROWNLEE W, Bourdette D, Broadley S, Killestein J, et al
    Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
    Neurology. 2020 Apr 2. pii: WNL.0000000000009507.
    PubMed     Abstract available


    March 2020
  148. CARVALHO NETO EG, Gomes MF, Dos Santos IP, Monteiro MD, et al
    Teaching Video NeuroImages: Useful bedside testing for myasthenia gravis: The phenomenon of enhanced ptosis.
    Neurology. 2020 Mar 31. pii: WNL.0000000000009238.
    PubMed    


  149. DE MEEL RHP, Keene KR, Wirth MA, Weber KP, et al
    Repetitive ocular vestibular evoked myogenic potentials in myasthenia gravis.
    Neurology. 2020 Mar 26. pii: WNL.0000000000009306.
    PubMed     Abstract available


  150. GRONSETH GS, Barohn R, Narayanaswami P
    Practice advisory: Thymectomy for myasthenia gravis (practice parameter update): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2020 Mar 25. pii: WNL.0000000000009294.
    PubMed     Abstract available


  151. ARGYROPOULOS GPD, Moore L, Loane C, Roca-Fernandez A, et al
    Pathologic tearfulness after limbic encephalitis: A novel disorder and its neural basis.
    Neurology. 2020;94:e1320-e1335.
    PubMed     Abstract available


  152. YEH EA, Sormani MP
    Tracking therapies in MS: More evidence in favor of neurofilament.
    Neurology. 2020;94:465-466.
    PubMed    


  153. TINTORE M, Perez-Hoyos S, Otero-Romero S
    Author response: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2020;94:456-457.
    PubMed    


  154. JOKUBAITIS VG, Dobson R
    Reader response: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2020;94:455-456.
    PubMed    


  155. GANESH A, Galetta S
    Editors' note: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2020;94:455.
    PubMed    


  156. AMEZCUA L, Smith JB, Gonzales EG, Haraszti S, et al
    Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis.
    Neurology. 2020 Mar 9. pii: WNL.0000000000009210.
    PubMed     Abstract available


  157. RICE J, Woltjer R, Stienstra N, Sun E, et al
    Pearls & Oy-sters: Primary angiitis of the CNS presenting with recurrent intracranial hemorrhage.
    Neurology. 2020;94:e992-e995.
    PubMed    



  158. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.
    Neurology. 2020 Mar 2. pii: WNL.0000000000008670.
    PubMed    


    February 2020
  159. OBEIDAT AZ, Jassam YN, Hua LH, Cutter G, et al
    Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States.
    Neurology. 2020 Feb 27. pii: WNL.0000000000009096.
    PubMed     Abstract available


  160. BRANDSTADTER R, Ayeni O, Krieger SC, Harel NY, et al
    Detection of subtle gait disturbance and future fall risk in early multiple sclerosis.
    Neurology. 2020 Feb 26. pii: WNL.0000000000008938.
    PubMed     Abstract available


  161. FRONTZEK K, Carta M, Losa M, Epskamp M, et al
    Autoantibodies against the prion protein in individuals with PRNP mutations.
    Neurology. 2020 Feb 25. pii: WNL.0000000000009183.
    PubMed     Abstract available


  162. GRAVE C, Boucheron P, Rudant J, Mikaeloff Y, et al
    Seasonal influenza vaccine and Guillain-Barre syndrome: A self-controlled case series study.
    Neurology. 2020 Feb 25. pii: WNL.0000000000009180.
    PubMed     Abstract available


  163. CORTES-VICENTE E, Alvarez-Velasco R, Segovia S, Paradas C, et al
    Clinical and therapeutic features of myasthenia gravis in adults based on age at onset.
    Neurology. 2020 Feb 18. pii: WNL.0000000000008903.
    PubMed     Abstract available


  164. DELCOIGNE B, Manouchehrinia A, Barro C, Benkert P, et al
    Blood neurofilament light levels segregate treatment effects in multiple sclerosis.
    Neurology. 2020 Feb 11. pii: WNL.0000000000009097.
    PubMed     Abstract available


  165. MACARON G, Willis MA, Ontaneda D, Fernandez H, et al
    Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder.
    Neurology. 2020;94:273-275.
    PubMed    


  166. KAPOOR M, Spillane J, Englezou C, Sarri-Gonzalez S, et al
    Thromboembolic risk with IVIg: Incidence and risk factors in patients with inflammatory neuropathy.
    Neurology. 2020;94:e635-e638.
    PubMed     Abstract available


  167. LIPKA AF, Boldingh MI, van Zwet EW, Schreurs MWJ, et al
    Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome.
    Neurology. 2020;94:e511-e520.
    PubMed     Abstract available


    January 2020
  168. RINGELSTEIN M, Harmel J, Zimmermann H, Brandt AU, et al
    Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders.
    Neurology. 2020;94:e407-e418.
    PubMed     Abstract available


  169. NEUMANN B, Angstwurm K, Mergenthaler P, Kohler S, et al
    Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases.
    Neurology. 2020;94:e299-e313.
    PubMed     Abstract available


  170. HERRAETS IJT, Goedee HS, Telleman JA, van Eijk RPA, et al
    Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies.
    Neurology. 2020 Jan 20. pii: WNL.0000000000008978.
    PubMed     Abstract available


  171. HARTUNG DM, Johnston KA, Geddes J, Bourdette DN, et al
    Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis.
    Neurology. 2020 Jan 15. pii: WNL.0000000000008936.
    PubMed     Abstract available


  172. KUNCHOK A, Krecke KN, Flanagan EP, Jitprapaikulsan J, et al
    Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)?
    Neurology. 2020;94:85-88.
    PubMed    


  173. HARDING K, Zhu F, Alotaibi M, Duggan T, et al
    Multiple cause of death analysis in multiple sclerosis: A population-based study.
    Neurology. 2020 Jan 13. pii: WNL.0000000000008907.
    PubMed     Abstract available


  174. MARRIE RA, O'Mahony J, Maxwell C, Ling V, et al
    Increased mental health care use by mothers of children with multiple sclerosis.
    Neurology. 2020 Jan 9. pii: WNL.0000000000008871.
    PubMed     Abstract available


    December 2019
  175. ZALOUM A, Falet JR, Elkrief A, Chalk C, et al
    Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma.
    Neurology. 2019 Dec 30. pii: WNL.0000000000008860.
    PubMed    


  176. MATTOZZI S, Sabater L, Escudero D, Arino H, et al
    Hashimoto encephalopathy in the 21st century.
    Neurology. 2019 Dec 27. pii: WNL.0000000000008785.
    PubMed     Abstract available


  177. TYLER KL, Ruegg S
    The neuromythology of Hashimoto encephalopathy: The emperor has no clothes.
    Neurology. 2019 Dec 27. pii: WNL.0000000000008776.
    PubMed    


  178. OUDEMAN J, Eftimov F, Strijkers GJ, Schneiders JJ, et al
    Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies.
    Neurology. 2019 Dec 11. pii: WNL.0000000000008697.
    PubMed     Abstract available


  179. ROTSTEIN DL, Marrie RA, Maxwell C, Gandhi S, et al
    MS risk in immigrants in the McDonald era: A population-based study in Ontario, Canada.
    Neurology. 2019;93:e2203-e2215.
    PubMed     Abstract available


    November 2019
  180. LEE PKJ, Small JE, Vytopil M
    Teaching NeuroImages: Autoimmune glial fibrillary acidic protein meningoencephalomyelitis.
    Neurology. 2019;93:e2076-e2077.
    PubMed    


  181. SAVRANSKY A, Rubstein A, Rios MH, Vergel SL, et al
    Prognostic indicators of improvement with therapeutic plasma exchange in pediatric demyelination.
    Neurology. 2019;93:e2065-e2073.
    PubMed     Abstract available


  182. M HARTUNG D, Alley L, A Johnston K, Bourdette DN, et al
    Qualitative study on the price of drugs for multiple sclerosis: Gaming the system.
    Neurology. 2019 Nov 25. pii: WNL.0000000000008653.
    PubMed     Abstract available


  183. TORABI T, Huttner A, Nowak RJ, Roy B, et al
    Clinical Reasoning: Progressive proximal weakness in a 56-year-old man with bone pain.
    Neurology. 2019;93:939-944.
    PubMed    


  184. MCKAY KA, Ernstsson O, Manouchehrinia A, Olsson T, et al
    Determinants of quality of life in pediatric- and adult-onset multiple sclerosis.
    Neurology. 2019 Nov 15. pii: WNL.0000000000008667.
    PubMed     Abstract available


  185. SHAN W, Liu X, Wang Q
    Teaching NeuroImages: (18)F-FDG-PET/SPM analysis in 3 different stages from a patient with LGI-1 autoimmune encephalitis.
    Neurology. 2019;93:e1917-e1918.
    PubMed    


  186. WATERS P, Vincent A
    Myelin oligodendrocyte glycoprotein CSF testing needs testing.
    Neurology. 2019;93:871-872.
    PubMed    


  187. MARIOTTO S, Gajofatto A, Batzu L, Delogu R, et al
    Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases.
    Neurology. 2019;93:e1867-e1872.
    PubMed     Abstract available


  188. ROCCA MA, Valsasina P, Meani A, Gobbi C, et al
    Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
    Neurology. 2019;93:e1852-e1866.
    PubMed     Abstract available


  189. HUPPERTS R, Smolders J, Vieth R, Holmoy T, et al
    Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon beta-1a.
    Neurology. 2019;93:e1906-e1916.
    PubMed     Abstract available


  190. BINZER S, McKay KA, Brenner P, Hillert J, et al
    Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
    Neurology. 2019 Nov 8. pii: WNL.0000000000008617.
    PubMed     Abstract available


    October 2019
  191. RUDANT J, Dupont A, Mikaeloff Y, Bolgert F, et al
    Author response: Surgery and risk of Guillain-Barre syndrome: A French nationwide epidemiologic study.
    Neurology. 2019;93:818.
    PubMed    


  192. STEINER I
    Reader response: Surgery and risk of Guillain-Barre syndrome: A French nationwide epidemiologic study.
    Neurology. 2019;93:817-818.
    PubMed    


  193. SIEGLER JE 3RD, Galetta S
    Editors' note: Surgery and risk of Guillain-Barre syndrome: A French nationwide epidemiologic study.
    Neurology. 2019;93:817.
    PubMed    


  194. MURARO PA, Cohen JA
    Complex intensive treatment shows promise against a complex aggressive disease.
    Neurology. 2019;93:776-777.
    PubMed    


  195. YAO MS, Chen S, Liu J
    Mystery Case: Cowden syndrome presenting with paraneoplastic encephalitis.
    Neurology. 2019;93:814-816.
    PubMed    


  196. MATHIS S, Le Masson G, Vallat JM
    Early clinicopathologic description of nodoparanodopathy in the 19th century.
    Neurology. 2019;93:788-792.
    PubMed     Abstract available


  197. BURT RK, Balabanov R, Han X, Burns C, et al
    Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica.
    Neurology. 2019;93:e1732-e1741.
    PubMed     Abstract available


  198. VEENHUIZEN Y, Cup EHC, Jonker MA, Voet NBM, et al
    Self-management program improves participation in patients with neuromuscular disease: A randomized controlled trial.
    Neurology. 2019;93:e1720-e1731.
    PubMed     Abstract available


  199. SORMANI MP, Naismith RT
    Measuring disability in multiple sclerosis: Walking plus much more.
    Neurology. 2019 Oct 22. pii: WNL.0000000000008515.
    PubMed    


  200. GOLDMAN MD, LaRocca NG, Rudick RA, Hudson LD, et al
    Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data.
    Neurology. 2019 Oct 22. pii: WNL.0000000000008519.
    PubMed     Abstract available



  201. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:769.
    PubMed    


  202. RAE-GRANT AD
    Author response: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:765.
    PubMed    


  203. TRAN KR
    Reader response: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:764-765.
    PubMed    


  204. GANESH A, Galetta S
    Editors' note: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:764.
    PubMed    


  205. VAN KEMPEN ZLE, Doesburg D, Dekker I, Lissenberg-Witte BI, et al
    The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms.
    Neurology. 2019;93:e1579-e1586.
    PubMed     Abstract available


  206. DUBEY D, Jitprapaikulsan J, Bi H, Do Campo RV, et al
    Amphiphysin-IgG autoimmune neuropathy: A recognizable clinicopathologic syndrome.
    Neurology. 2019 Oct 17. pii: WNL.0000000000008472.
    PubMed     Abstract available


  207. PAPP V, Illes Z, Magyari M, Koch-Henriksen N, et al
    Author response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark.
    Neurology. 2019;93:723.
    PubMed    


  208. ASGARI N, Flanagan EP
    Reader response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark.
    Neurology. 2019;93:722-723.
    PubMed    


  209. PINAL-FERNANDEZ I, Mecoli CA, Casal-Dominguez M, Pak K, et al
    More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies.
    Neurology. 2019 Oct 8. pii: WNL.0000000000008443.
    PubMed     Abstract available


  210. CLIFFORD DB, Tyler KL
    Dosing interval of natalizumab in MS: Do good things come to those who wait?
    Neurology. 2019;93:655-656.
    PubMed    


  211. RYERSON LZ, Foley J, Chang I, Kister I, et al
    Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
    Neurology. 2019;93:e1452-e1462.
    PubMed     Abstract available


  212. TUR C, Kalincik T, Oh J, Sormani MP, et al
    Head-to-head drug comparisons in multiple sclerosis: Urgent action needed.
    Neurology. 2019 Oct 7. pii: WNL.0000000000008319.
    PubMed     Abstract available


    September 2019
  213. WATANABE M, Nakamura Y, Michalak Z, Isobe N, et al
    Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
    Neurology. 2019;93:e1299-e1311.
    PubMed     Abstract available


  214. PFUHL C, Grittner U, Giess RM, Scheel M, et al
    Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis.
    Neurology. 2019 Sep 9. pii: WNL.0000000000008237.
    PubMed     Abstract available


  215. EIJLERS AJC, Dekker I, Steenwijk MD, Meijer KA, et al
    Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis.
    Neurology. 2019 Sep 4. pii: WNL.0000000000008198.
    PubMed     Abstract available


  216. BARKHOF F, Kappos L, Wolinsky JS, Li DKB, et al
    Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Neurology. 2019 Sep 4. pii: WNL.0000000000008189.
    PubMed     Abstract available


  217. CAMMAERT LA, Macleod AD, Mackay GA, Duncan CW, et al
    Reversible tongue atrophy in Lambert-Eaton myasthenic syndrome.
    Neurology. 2019;93:459-460.
    PubMed    


  218. WONG YYM, Bruijstens AL, Barro C, Michalak Z, et al
    Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes.
    Neurology. 2019;93:e968-e974.
    PubMed     Abstract available


    August 2019

  219. Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG.
    Neurology. 2019 Aug 29. pii: WNL.0000000000008232.
    PubMed    


  220. FAREZ MF, Correale J, Armstrong MJ, Rae-Grant A, et al
    Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019 Aug 28. pii: WNL.0000000000008157.
    PubMed     Abstract available


  221. YEH EA, Graves J
    Vaccination: Not a trigger for MS.
    Neurology. 2019;93:377-378.
    PubMed    


  222. LAW LY, Riminton DS, Nguyen M, Barnett MH, et al
    The spectrum of immune-mediated and inflammatory lesions of the brainstem: Clues to diagnosis.
    Neurology. 2019;93:390-405.
    PubMed     Abstract available


  223. SUMOWSKI JF, Muhlert N
    Dalfampridine improves slowed processing speed in MS: Picking up the pace.
    Neurology. 2019;93:325-326.
    PubMed    


  224. MADIGAN NN, Liewluck T, Milone M, Naddaf E, et al
    Necrotizing autoimmune myopathy with tubular aggregates.
    Neurology. 2019;93:313-314.
    PubMed    


  225. SECHI E, Keegan BM, Kaufmann TJ, Kantarci OH, et al
    Unilateral motor progression in MS: Association with a critical corticospinal tract lesion.
    Neurology. 2019;93:e628-e634.
    PubMed     Abstract available


  226. ZIVADINOV R, Bergsland N, Hagemeier J, Ramasamy DP, et al
    Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.
    Neurology. 2019;93:e611-e623.
    PubMed     Abstract available


  227. SNYDER J, Turner L
    Crowdfunding for stem cell-based interventions to treat neurologic diseases and injuries.
    Neurology. 2019;93:252-258.
    PubMed     Abstract available


  228. HONORAT JA, Lopez-Chiriboga AS, Kryzer TJ, Komorowski L, et al
    Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG.
    Neurology. 2019 Aug 1. pii: WNL.0000000000008061.
    PubMed     Abstract available


    July 2019
  229. HAPFELMEIER A, Gasperi C, Donnachie E, Hemmer B, et al
    A large case-control study on vaccination as risk factor for multiple sclerosis.
    Neurology. 2019 Jul 30. pii: WNL.0000000000008012.
    PubMed     Abstract available


  230. SAUCEDO M, Chertcoff A, Bandeo L, Leon Cejas L, et al
    Mystery Case: A 78-year-old man with a gait disorder.
    Neurology. 2019;93:223-227.
    PubMed    


  231. MANDEL-BREHM C, Retallack H, Knudsen GM, Yamana A, et al
    Exploratory proteomic analysis implicates the alternative complement cascade in primary CNS vasculitis.
    Neurology. 2019;93:e433-e444.
    PubMed     Abstract available


  232. ALGAEED M
    Author response: Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2019;93:184.
    PubMed    


  233. ROBBINS NM, Mozaffar T, Mammen AL, Liewluck T, et al
    Reader response: Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2019;93:183-184.
    PubMed    


  234. GANESH A, Galetta S
    Editors' note: Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2019;93:182-183.
    PubMed    


  235. MATEEN FJ
    Multiple sclerosis in resource-limited settings: Research opportunities in an unequal world.
    Neurology. 2019;93:176-180.
    PubMed     Abstract available


  236. AL BANNA M, Reeder S, Ghannam M, Robertson J, et al
    Teaching NeuroImages: A case of Vogt-Koyanagi-Harada disease with bilateral retinal detachment.
    Neurology. 2019;93:e421.
    PubMed    


  237. DE GIGLIO L, De Luca F, Gurreri F, Ferrante I, et al
    Effect of dalfampridine on information processing speed impairment in multiple sclerosis.
    Neurology. 2019 Jul 22. pii: WNL.0000000000007970.
    PubMed     Abstract available


  238. TITULAER MJ, Irani SR, Lassmann H
    PDE10A antibodies in autoimmune encephalitis: A possible marker of cancer immunotherapy?
    Neurology. 2019 Jul 17. pii: WNL.0000000000007965.
    PubMed    


  239. ZEKERIDOU A, Kryzer T, Guo Y, Hassan A, et al
    Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.
    Neurology. 2019 Jul 17. pii: WNL.0000000000007971.
    PubMed     Abstract available


  240. SCHMIDT M, Westemeier J, Gross D
    The two lives of neurologist Helmut J. Bauer (1914-2008): Renowned MS specialist and National Socialist.
    Neurology. 2019;93:109-113.
    PubMed     Abstract available


  241. LAPLAUD DA, Casey R, Barbin L, Debouverie M, et al
    Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.
    Neurology. 2019 Jul 12. pii: WNL.0000000000007938.
    PubMed     Abstract available


  242. HERSH CM, Marrie RA
    Harnessing real-world data to inform treatment decisions in multiple sclerosis.
    Neurology. 2019 Jul 12. pii: WNL.0000000000007934.
    PubMed    


  243. JONSSON DI, Sveinsson O, Hakim R, Brundin L, et al
    Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study.
    Neurology. 2019;93:e181-e189.
    PubMed     Abstract available


  244. CICHOWSKI AJ, Lawson VH
    Patient hand and artistic depiction of chronic inflammatory demyelinating polyradiculoneuropathy.
    Neurology. 2019;93:35-36.
    PubMed    


    June 2019
  245. SECHI E, Shosha E, Williams JP, Pittock SJ, et al
    Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology.
    Neurology. 2019 Jun 24. pii: WNL.0000000000007828.
    PubMed     Abstract available


  246. DI LUCA DG, Landman J, Ortega MR, Gultekin SH, et al
    Clinical Reasoning: A 47-year-old man with diffuse white matter disease and rapidly progressive dementia.
    Neurology. 2019;92:e2832-e2837.
    PubMed    


  247. VERBOON C, Doets AY, Galassi G, Davidson A, et al
    Current treatment practice of Guillain-Barre syndrome.
    Neurology. 2019 Jun 7. pii: WNL.0000000000007719.
    PubMed     Abstract available


  248. GESSANI A, Cavallieri F, Budriesi C, Zucchi E, et al
    Pearls & Oy-sters: Paroxysmal dysarthria-ataxia syndrome: Acoustic analysis in a case of antiphospholipid syndrome.
    Neurology. 2019;92:e2727-e2731.
    PubMed    


    May 2019
  249. WAUBANT E, Banwell B, Wassmer E, Sormani MP, et al
    Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.
    Neurology. 2019;92:e2538-e2549.
    PubMed     Abstract available


  250. HOWARD JF JR, Bril V, Burns TM, Mantegazza R, et al
    Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Neurology. 2019 May 22. pii: WNL.0000000000007600.
    PubMed     Abstract available


  251. GUIDON AC, Juel VC
    Efgartigimod: A novel antibody depletion therapy in myasthenia gravis.
    Neurology. 2019 May 22. pii: WNL.0000000000007605.
    PubMed    


  252. LANNUZEL A, Ferge JL, Lobjois Q, Signate A, et al
    Long-term outcome in neuroZika: When biological diagnosis matters.
    Neurology. 2019;92:e2406-e2420.
    PubMed     Abstract available


  253. MAMMELE S, Thompson KS, Abe KK
    A rapidly fatal case of anti-NMDA receptor encephalitis due to acute brain edema and herniation.
    Neurology. 2019;92:1014-1016.
    PubMed    


  254. MCKAY KA, Hillert J, Manouchehrinia A
    Long-term disability progression ofpediatric-onset multiple sclerosis.
    Neurology. 2019 May 15. pii: WNL.0000000000007647.
    PubMed     Abstract available


  255. NA S, Lee ES, Kim YD
    Teaching NeuroImages: Pterygoid myositis mimicking giant cell arteritis.
    Neurology. 2019;92:e2297.
    PubMed    


  256. DE BRUIJN MAAM, van Sonderen A, van Coevorden-Hameete MH, Bastiaansen AEM, et al
    Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis.
    Neurology. 2019;92:e2185-e2196.
    PubMed     Abstract available


  257. PAPADOPOULOU A, Gaetano L, Pfister A, Altermatt A, et al
    Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway.
    Neurology. 2019;92:e2240-e2249.
    PubMed     Abstract available


  258. BLANKENBACH K, Schwab N, Hofner B, Adams O, et al
    Natalizumab-associated progressive multifocal leukoencephalopathy in Germany.
    Neurology. 2019;92:e2232-e2239.
    PubMed     Abstract available


  259. CALABRESE M, Gasperini C, Tortorella C, Schiavi G, et al
    "Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study.
    Neurology. 2019 May 1. pii: WNL.0000000000007573.
    PubMed     Abstract available


  260. BROWNLEE WJ
    Differential diagnosis of multiple sclerosis: The better explanations in clinical practice.
    Neurology. 2019 May 1. pii: WNL.0000000000007566.
    PubMed    


    April 2019
  261. DI LUCA DG, De Leon-Benedetti A, Williamson S, Irving LT, et al
    Teaching Video NeuroImages: A patient with Holmes tremor due to demyelinating lesion of the inferior cerebellar peduncle.
    Neurology. 2019;92:e2179-e2180.
    PubMed    


  262. MAILLART E, Mochel F, Acquaviva C, Maisonobe T, et al
    Severe transient myopathy in a progressive multiple sclerosis patient with high-dose biotin.
    Neurology. 2019 Apr 26. pii: WNL.0000000000007576.
    PubMed    


  263. ZHANG C, Wang SG, Wang Y, Liu XL, et al
    Teaching Video NeuroImages: Cautious walking gait in siblings with hereditary hyperekplexia.
    Neurology. 2019;92:e2068-e2069.
    PubMed    


  264. VILLOSLADA P, Green AJ, Galetta S
    Personalizing medical care for MS patients: Monitoring brainstem damage by infrared oculography.
    Neurology. 2019 Apr 19. pii: WNL.0000000000007493.
    PubMed    


  265. NIJ BIJVANK JA, van Rijn LJ, Balk LJ, Tan HS, et al
    Diagnosing and quantifying a common deficit in multiple sclerosis: Internuclear ophthalmoplegia.
    Neurology. 2019 Apr 19. pii: WNL.0000000000007499.
    PubMed     Abstract available


  266. BURON MD, Chalmer TA, Sellebjerg F, Frederiksen J, et al
    Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study.
    Neurology. 2019;92:e1811-e1820.
    PubMed     Abstract available


  267. BRITTON JW, Dalmau J
    Recognizing autoimmune encephalitis as a cause of seizures: Treating cause and not effect.
    Neurology. 2019 Apr 12. pii: WNL.0000000000007444.
    PubMed    


  268. MEHTA D, Miller C, Arnold DL, Bame E, et al
    Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
    Neurology. 2019;92:e1724-e1738.
    PubMed     Abstract available


  269. KILLESTEIN J, Reder AT
    Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring.
    Neurology. 2019;92:696-697.
    PubMed    


  270. WAUBANT E, Gilmore W
    Mind the gap: Quantifying gender representation as a first step to solve the problem?
    Neurology. 2019;92:698-699.
    PubMed    


  271. CORTESE M, Chitnis T, Ascherio A, Munger KL, et al
    Total intake of different minerals and the risk of multiple sclerosis.
    Neurology. 2019 Apr 3. pii: WNL.0000000000006800.
    PubMed     Abstract available


  272. MCDONNELL GV, Marriott JJ
    Patient-perceived risks of MS DMTs: Problems of communication and risk management?
    Neurology. 2019;92:647-648.
    PubMed    


  273. JOHANSEN A, Christensen SJ, Scheie D, Hojgaard JLS, et al
    Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.
    Neurology. 2019;92:663-674.
    PubMed     Abstract available


  274. MARRIE RA, Garland A, Schaffer SA, Fransoo R, et al
    Traditional risk factors may not explain increased incidence of myocardial infarction in MS.
    Neurology. 2019;92:e1624-e1633.
    PubMed     Abstract available


    March 2019
  275. CONWAY DS
    What is the impact of socioeconomic status on multiple sclerosis?
    Neurology. 2019;92:e1536-e1539.
    PubMed    


  276. GORIS A, Dubois B
    Leveraging human genetics to inform intervention strategies for multiple sclerosis.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007298.
    PubMed    


  277. THOMSON A, Horne R, Chung C, Marta M, et al
    Visibility and representation of women in multiple sclerosis research.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007276.
    PubMed     Abstract available


  278. HARROUD A, Morris JA, Forgetta V, Mitchell R, et al
    Effect of age at puberty on risk of multiple sclerosis: A mendelian randomization study.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007325.
    PubMed     Abstract available


  279. KALINCIK T
    Effectiveness of oral multiple sclerosis therapies in clinical context.
    Neurology. 2019 Mar 15. pii: WNL.0000000000007300.
    PubMed    


  280. DE MEO E, Meani A, Moiola L, Ghezzi A, et al
    Dynamic gray matter volume changes in pediatric multiple sclerosis: A 3.5-year MRI study.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007267.
    PubMed     Abstract available


  281. FOX RJ, Cosenza C, Cripps L, Ford P, et al
    A survey of risk tolerance to multiple sclerosis therapies.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007245.
    PubMed     Abstract available


  282. YEH EA, Eshaghi A
    Evolution of regional brain atrophy in children with multiple sclerosis: Gray matters.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007254.
    PubMed    


  283. BAR-OR A, Grove RA, Tolson JM, Derosier FJ, et al
    Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:543.
    PubMed    


  284. KEARNEY H
    Reader response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:542-543.
    PubMed    


  285. LEWIS A, Galetta S
    Editors' note: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:542.
    PubMed    


  286. YEH EA, Nakashima I
    Live-cell based assays are the gold standard for anti-MOG-Ab testing.
    Neurology. 2019;92:501-502.
    PubMed    


  287. NG PS, Dyck PJ, Laughlin RS, Thapa P, et al
    Lumbosacral radiculoplexus neuropathy: Incidence and the association with diabetes mellitus.
    Neurology. 2019;92:e1188-e1194.
    PubMed     Abstract available


  288. WATERS PJ, Komorowski L, Woodhall M, Lederer S, et al
    A multicenter comparison of MOG-IgG cell-based assays.
    Neurology. 2019;92:e1250-e1255.
    PubMed     Abstract available


  289. LAPUCCI C, Saitta L, Bommarito G, Sormani MP, et al
    How much do periventricular lesions assist in distinguishing migraine with aura from CIS?
    Neurology. 2019 Mar 8. pii: WNL.0000000000007266.
    PubMed     Abstract available


  290. CULPEPPER WJ, Marrie RA, Langer-Gould A, Wallin MT, et al
    Validation of an algorithm for identifying MS cases in administrative health claims datasets.
    Neurology. 2019;92:e1016-e1028.
    PubMed     Abstract available


  291. WALLIN MT, Culpepper WJ, Campbell JD, Nelson LM, et al
    The prevalence of MS in the United States: A population-based estimate using health claims data.
    Neurology. 2019;92:e1029-e1040.
    PubMed     Abstract available


  292. KUHLE J, Kropshofer H, Haering DA, Kundu U, et al
    Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
    Neurology. 2019;92:e1007-e1015.
    PubMed     Abstract available


  293. ZULUAGA MI, Otero-Romero S, Rovira A, Perez-Hoyos S, et al
    Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2019 Mar 1. pii: WNL.0000000000007178.
    PubMed     Abstract available


  294. CASAL-DOMINGUEZ M, Pinal-Fernandez I, Corse AM, Paik J, et al
    Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies.
    Neurology. 2019 Mar 1. pii: WNL.0000000000007188.
    PubMed     Abstract available


    February 2019
  295. HARDING KE, Wardle M, Carruthers R, Robertson N, et al
    Socioeconomic status and disability progression in multiple sclerosis: A multinational study.
    Neurology. 2019 Feb 22. pii: WNL.0000000000007190.
    PubMed     Abstract available


  296. OH J, Ontaneda D, Azevedo C, Klawiter EC, et al
    Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS.
    Neurology. 2019 Feb 20. pii: WNL.0000000000007099.
    PubMed     Abstract available


  297. KOCH-HENRIKSEN N
    Author response: Incidence of MS has increased markedly over 6 decades in Denmark particularly with late onset and in women.
    Neurology. 2019;92:397.
    PubMed    


  298. SAJEDI SA
    Reader response: Incidence of MS has increased markedly over 6 decades in Denmark particularly with late onset and in women.
    Neurology. 2019;92:397.
    PubMed    


  299. BENARROCH EE
    Autonomic nervous system and neuroimmune interactions: New insights and clinical implications.
    Neurology. 2019;92:377-385.
    PubMed    


  300. DI LUCA DG, Bette S, Singer C, Luca C, et al
    Teaching NeuroImages: Severe spasms resembling status dystonicus as an unusual presentation of stiff-person syndrome.
    Neurology. 2019;92:e748.
    PubMed    


  301. SECHI E, Parks NE, Koeller KK, Flanagan EP, et al
    Hypertrophic olivary degeneration mimics relapse in neuromyelitis optica spectrum disorder.
    Neurology. 2019;92:343-344.
    PubMed    


  302. DALLA COSTA G, Martinelli V, Sangalli F, Moiola L, et al
    Prognostic value of serum neurofilaments in patients with clinically isolated syndromes.
    Neurology. 2019;92:e733-e741.
    PubMed     Abstract available


  303. ROCHA EA, Topcuoglu MA, Silva GS, Singhal AB, et al
    RCVS2 score and diagnostic approach for reversible cerebral vasoconstriction syndrome.
    Neurology. 2019;92:e639-e647.
    PubMed     Abstract available


  304. BERGER T, Stuve O
    Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis.
    Neurology. 2019 Feb 8. pii: WNL.0000000000007022.
    PubMed    


  305. XU SC, Kardon RH, Leavitt JA, Flanagan EP, et al
    Optical coherence tomography is highly sensitive in detecting prior optic neuritis.
    Neurology. 2019;92:e527-e535.
    PubMed     Abstract available


    January 2019
  306. COHEN J, Sotoca J, Gandhi S, Yeshokumar AK, et al
    Autoimmune encephalitis: A costly condition.
    Neurology. 2019 Jan 23. pii: WNL.0000000000006990.
    PubMed     Abstract available


  307. BERGER JR, Cree BA, Greenberg B, Hemmer B, et al
    Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Neurology. 2019;92:151.
    PubMed    


  308. LALIVE PH, Roth S, Du Pasquier R
    Reader response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Neurology. 2019;92:151.
    PubMed    


  309. RUEGG S, Yeh EA, Honnorat J
    Forecasting outcomes in anti-NMDAR encephalitis: Clearer prognostic markers needed.
    Neurology. 2019;92:119-120.
    PubMed    


  310. BALU R, McCracken L, Lancaster E, Graus F, et al
    A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis.
    Neurology. 2019;92:e244-e252.
    PubMed     Abstract available


  311. ZETTERBERG H, Svenningsson A
    Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006906.
    PubMed    


  312. HONCE JM, Nair KV, Sillau S, Valdez B, et al
    Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006916.
    PubMed     Abstract available


  313. COHEN BA
    Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006924.
    PubMed    



  314. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:112.
    PubMed    


  315. RAE-GRANT A
    Author response: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:110-111.
    PubMed    


  316. SALTONSTALL L
    Reader response: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:109-110.
    PubMed    


  317. LEWIS A, Galetta S
    Editors' note: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:109.
    PubMed    


    December 2018
  318. PAPPOLLA A, Midaglia L, Boix Rodriguez CP, Puig AA, et al
    Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis.
    Neurology. 2018 Dec 26. pii: WNL.0000000000006801.
    PubMed    


  319. GASPERINI C, Prosperini L, Tintore M, Sormani MP, et al
    Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.
    Neurology. 2018 Dec 26. pii: WNL.0000000000006810.
    PubMed     Abstract available


    November 2018
  320. MARRIE RA, Butzkueven H, Ascherio A
    Obesity and brain volume loss in multiple sclerosis.
    Neurology. 2018 Nov 14. pii: WNL.0000000000006638.
    PubMed    


  321. MAHLER C, Unterrainer M, Muth C, Egensperger R, et al
    Imaging microglial activation in tacrolimus-associated CNS vasculitis with translocator protein PET.
    Neurology. 2018;91:936-937.
    PubMed    


  322. RUCK T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, et al
    Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.
    Neurology. 2018 Nov 7. pii: WNL.0000000000006648.
    PubMed     Abstract available


    October 2018
  323. BROWNLEE WJ
    Misdiagnosis of multiple sclerosis: If you have a hammer, everything looks like a nail?
    Neurology. 2018 Oct 31. pii: WNL.0000000000006584.
    PubMed    


  324. SOLOMON AJ, Naismith RT, Cross AH
    Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice.
    Neurology. 2018 Oct 31. pii: WNL.0000000000006583.
    PubMed     Abstract available


  325. PORTACCIO E, Amato MP
    Author response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:851.
    PubMed    


  326. SOTGIU S, Eusebi A, Begliuomini C, Guerini FR, et al
    Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:850.
    PubMed    


  327. PROSCHMANN U, Akgun K, Ziemssen T
    Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:849-850.
    PubMed    


  328. LEWIS A, Galetta S
    Editors' note: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:849.
    PubMed    


  329. KRYSKO KM, Graves J, Rensel M, Weinstock-Guttman B, et al
    Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US.
    Neurology. 2018 Oct 17. pii: WNL.0000000000006471.
    PubMed     Abstract available


  330. BASAL E, Zalewski N, Kryzer TJ, Hinson SR, et al
    Paraneoplastic neuronal intermediate filament autoimmunity.
    Neurology. 2018 Oct 3. pii: WNL.0000000000006435.
    PubMed     Abstract available


  331. ALGAEED M, Mukharesh L, Heinzelmann M, Kaminski HJ, et al
    Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2018;91:e1365-e1367.
    PubMed    


    September 2018
  332. CAVALLA P, Gilmore W
    Pregnancy in multiple sclerosis: Data from an administrative claims database.
    Neurology. 2018 Sep 28. pii: WNL.0000000000006371.
    PubMed    


  333. BAHEERATHAN A, McNamara C, Kalam S, Rane N, et al
    The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab.
    Neurology. 2018;91:572-573.
    PubMed    



  334. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2018;91:538.
    PubMed    


    August 2018
  335. MIDAGLIA L, Gratacos M, Caronna E, Raguer N, et al
    Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.
    Neurology. 2018 Aug 24. pii: WNL.0000000000006251.
    PubMed    


  336. RUDANT J, Dupont A, Mikaeloff Y, Bolgert F, et al
    Surgery and risk of Guillain-Barre syndrome: A French nationwide epidemiologic study.
    Neurology. 2018 Aug 24. pii: WNL.0000000000006246.
    PubMed     Abstract available


  337. BROWNLEE WJ, Miszkiel KA, Tur C, Barkhof F, et al
    Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis.
    Neurology. 2018 Aug 17. pii: WNL.0000000000006207.
    PubMed     Abstract available


    July 2018
  338. BEDARF JR, Nelles M, Reimann J, Paus S, et al
    Teaching Video NeuroImages: Propriospinal myoclonus as a sequela of Guillain-Barre syndrome.
    Neurology. 2018;91:e297-e299.
    PubMed    


  339. MARQUES-MATOS C, Melo C, Sampaio M, Rodrigues E, et al
    Child Neurology: Treatable bilateral striatal lesions related to anti-dopamine 2 receptor autoimmunity.
    Neurology. 2018;91:98-101.
    PubMed    


    June 2018
  340. TSAGKAS C, Magon S, Gaetano L, Pezold S, et al
    Spinal cord volume loss: A marker of disease progression in multiple sclerosis.
    Neurology. 2018 Jun 27. pii: WNL.0000000000005853.
    PubMed     Abstract available


  341. PRADOS F, Barkhof F
    Spinal cord atrophy rates: Ready for prime time in multiple sclerosis clinical trials?
    Neurology. 2018 Jun 27. pii: WNL.0000000000005873.
    PubMed    


  342. HAGENS MHJ, Burggraaff J, Kilsdonk ID, de Vos ML, et al
    Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.
    Neurology. 2018 Jun 20. pii: WNL.0000000000005825.
    PubMed     Abstract available


  343. VITT JR, Kreple C, Mahmood N, Dickerson E, et al
    Autoimmune pancerebellitis associated with pembrolizumab therapy.
    Neurology. 2018 Jun 6. pii: WNL.0000000000005781.
    PubMed    


  344. PROSPERINI L, Lucchini M, Haggiag S, Bellantonio P, et al
    Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
    Neurology. 2018 Jun 6. pii: WNL.0000000000005772.
    PubMed     Abstract available


    May 2018
  345. LEHMANN HC, Compston A, Hartung HP
    150th anniversary of clinical description of multiple sclerosis: Leopold Ordenstein's legacy.
    Neurology. 2018;90:1011-1016.
    PubMed     Abstract available


  346. KIM DD, Ho C, King R, Morrow SA, et al
    Pearls & Oy-sters: An unusual neuropsychiatric manifestation of systemic lupus erythematosus.
    Neurology. 2018;90:e1929-e1932.
    PubMed    


  347. LIEWLUCK T
    Author response: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:990.
    PubMed    


  348. BUDHRAM A
    Reader response: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:990.
    PubMed    


  349. KARAM C, Galetta S
    Editors' note: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:989.
    PubMed    


  350. SCALFARI A, Romualdi C, Nicholas RS, Mattoscio M, et al
    The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis.
    Neurology. 2018 May 16. pii: WNL.0000000000005685.
    PubMed     Abstract available


  351. SHANKLIN A, Cox A, Ahmed HMA, Lieberman A, et al
    Clinical Reasoning: A 77-year-old man presenting with episodic expressive aphasia.
    Neurology. 2018;90:e1822-e1826.
    PubMed    


  352. DE LORENZO R, Pinal-Fernandez I, Huang W, Albayda J, et al
    Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies.
    Neurology. 2018 May 4. pii: WNL.0000000000005638.
    PubMed     Abstract available


  353. FRANKLIN GM, McDonnell G
    Free health care, great data, and new clues on multiple sclerosis.
    Neurology. 2018 May 2. pii: WNL.0000000000005593.
    PubMed    


  354. LOPEZ CHIRIBOGA AS, Matsumoto J, Sorenson E, Klein CJ, et al
    Teaching Video NeuroImages: Acquired focal neuromyotonia in LGI-1 autoimmunity.
    Neurology. 2018;90:e1636-e1637.
    PubMed    


    April 2018
  355. GERARDI C, Bertele' V, Rossi S, Garattini S, et al
    Preapproval and postapproval evidence on drugs for multiple sclerosis.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005561.
    PubMed     Abstract available


  356. BAR-OR A, Grove RA, Austin DJ, Tolson JM, et al
    Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005516.
    PubMed     Abstract available


  357. COBO-CALVO A, Ruiz A, Maillart E, Audoin B, et al
    Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005560.
    PubMed     Abstract available


  358. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:789-800.
    PubMed     Abstract available


  359. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:777-788.
    PubMed     Abstract available


  360. HEWETT K, Sanders DB, Grove RA, Broderick CL, et al
    Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.
    Neurology. 2018;90:e1425-e1434.
    PubMed     Abstract available


  361. PEDROSO JL, Dutra LA, Espay AJ, Hoftberger R, et al
    Video NeuroImages: Head titubation in anti-mGluR1 autoantibody-associated cerebellitis.
    Neurology. 2018;90:746-747.
    PubMed    


  362. CORREALE J, Ysrraelit MC, Benarroch EE
    Metabolic coupling of axons and glial cells: Implications for multiple sclerosis progression.
    Neurology. 2018;90:737-744.
    PubMed    


    March 2018
  363. FERRARO D, Camera V, Vitetta F, Zennaro M, et al
    Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
    Neurology. 2018 Mar 30. pii: WNL.0000000000005417.
    PubMed    


  364. SAARELA M, Senthil K, Jones J, Tienari PJ, et al
    Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.
    Neurology. 2018 Mar 30. pii: WNL.0000000000005420.
    PubMed    


  365. FRATTINI E, Monfrini E, Bitetto G, Ferrari B, et al
    Clinical Reasoning: A 75-year-old man with parkinsonism, mood depression, and weight loss.
    Neurology. 2018;90:572-575.
    PubMed    


  366. ROTSTEIN DL, Chen H, Wilton AS, Kwong JC, et al
    Temporal trends in multiple sclerosis prevalence and incidence in a large population.
    Neurology. 2018 Mar 16. pii: WNL.0000000000005331.
    PubMed     Abstract available


  367. GAETANO L, Haring DA, Radue EW, Mueller-Lenke N, et al
    Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
    Neurology. 2018 Mar 14. pii: WNL.0000000000005292.
    PubMed     Abstract available


  368. SCHOONHEIM MM, Ciccarelli O
    The value of including thalamic atrophy as a clinical trial endpoint in multiple sclerosis.
    Neurology. 2018 Mar 14. pii: WNL.0000000000005279.
    PubMed    


  369. MCKAY KA, Tremlett H, Fisk JD, Zhang T, et al
    Psychiatric comorbidity is associated with disability progression in multiple sclerosis.
    Neurology. 2018 Mar 9. pii: WNL.0000000000005302.
    PubMed     Abstract available


  370. MILLER AE, Calabresi PA
    Central vein sign in multiple sclerosis: Ready for front and center?
    Neurology. 2018 Mar 7. pii: WNL.0000000000005241.
    PubMed    


  371. TREMLETT H, Zhu F, Ascherio A, Munger KL, et al
    Sun exposure over the life course and associations with multiple sclerosis.
    Neurology. 2018 Mar 7. pii: WNL.0000000000005257.
    PubMed     Abstract available


    February 2018
  372. PATIL A, Shree R, Naheed D, Goyal MK, et al
    Pearls & Oy-sters: Paraneoplastic cerebral vasculitis: Rare cause of spontaneous convexity subarachnoid hemorrhage.
    Neurology. 2018;90:e815-e817.
    PubMed    


  373. CHATAWAY J, Martin K, Barrell K, Sharrack B, et al
    Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.
    Neurology. 2018 Feb 21. pii: WNL.0000000000005118.
    PubMed     Abstract available


  374. BATEMAN EM, Schleicher WE, Smith EJ, Sweet DR, et al
    Journal Club: MRI reveals acute inflammation in cortical lesions during early MS.
    Neurology. 2018;90:e724-e726.
    PubMed     Abstract available


  375. PORTACCIO E, Annovazzi P, Ghezzi A, Zaffaroni M, et al
    Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005067.
    PubMed     Abstract available


  376. PORTACCIO E, Moiola L, Martinelli V, Annovazzi P, et al
    Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005068.
    PubMed     Abstract available


  377. ALROUGHANI R, Alowayesh MS, Ahmed SF, Behbehani R, et al
    Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era.
    Neurology. 2018 Feb 2. pii: WNL.0000000000005065.
    PubMed     Abstract available


  378. SALVARANI C, Brown RD Jr, Christianson TJH, Huston J 3rd, et al
    Primary central nervous system vasculitis associated with lymphoma.
    Neurology. 2018 Feb 2. pii: WNL.0000000000005062.
    PubMed     Abstract available


    January 2018
  379. BENNETT S, Leavitt VM
    An intervention to improve balance in persons with multiple sclerosis.
    Neurology. 2018 Jan 31. pii: WNL.0000000000005038.
    PubMed    


  380. HEBERT JR, Corboy JR, Vollmer T, Forster JE, et al
    Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS).
    Neurology. 2018 Jan 31. pii: WNL.0000000000005013.
    PubMed     Abstract available


  381. WEHRUM T, Beume LA, Stich O, Mader I, et al
    Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis.
    Neurology. 2018 Jan 19. pii: WNL.0000000000004950.
    PubMed     Abstract available


  382. PETERSEN ER, Oturai AB, Koch-Henriksen N, Magyari M, et al
    Smoking affects the interferon beta treatment response in multiple sclerosis.
    Neurology. 2018 Jan 17. pii: WNL.0000000000004949.
    PubMed     Abstract available


  383. SUMOWSKI JF, Benedict R, Enzinger C, Filippi M, et al
    Cognition in multiple sclerosis: State of the field and priorities for the future.
    Neurology. 2018 Jan 17. pii: WNL.0000000000004977.
    PubMed     Abstract available


  384. ALLENBACH Y, Arouche-Delaperche L, Preusse C, Radbruch H, et al
    Necrosis in anti-SRP(+) and anti-HMGCR(+)myopathies: Role of autoantibodies and complement.
    Neurology. 2018 Jan 12. pii: WNL.0000000000004923.
    PubMed     Abstract available


  385. ZHANG T, Tremlett H, Zhu F, Kingwell E, et al
    Effects of physical comorbidities on disability progression in multiple sclerosis.
    Neurology. 2018 Jan 3. pii: WNL.0000000000004885.
    PubMed     Abstract available


    December 2017
  386. PISA M, Guerrieri S, Di Maggio G, Medaglini S, et al
    No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS.
    Neurology. 2017;89:2469-2475.
    PubMed     Abstract available


  387. DUBEY D, Lennon VA, Gadoth A, Pittock SJ, et al
    Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases.
    Neurology. 2017 Dec 8. pii: WNL.0000000000004803.
    PubMed     Abstract available


  388. LOREFICE L, Fenu G, Gerevini S, Frau J, et al
    PML in a person with multiple sclerosis: Is teriflunomide the felon?
    Neurology. 2017 Dec 6. pii: WNL.0000000000004804.
    PubMed    


  389. FITZGERALD KC, Tyry T, Salter A, Cofield SS, et al
    Diet quality is associated with disability and symptom severity in multiple sclerosis.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004768.
    PubMed     Abstract available


  390. SUMOWSKI JF, McDonnell GV, Bourdette D
    Diet in multiple sclerosis: Science takes a seat at the table.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004775.
    PubMed    


    November 2017
  391. BURNOR E, Yang L, Zhou H, Patterson KR, et al
    Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies.
    Neurology. 2017 Nov 29. pii: WNL.0000000000004773.
    PubMed     Abstract available


  392. KLAWITER EC, Bove R, Elsone L, Alvarez E, et al
    High risk of postpartum relapses in neuromyelitis optica spectrum disorder.
    Neurology. 2017;89:2238-2244.
    PubMed     Abstract available


  393. LARONI A, Signori A, Maniscalco GT, Lanzillo R, et al
    Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.
    Neurology. 2017;89:2222-2229.
    PubMed     Abstract available


  394. KARCESKI S
    How comorbid conditions affect the choice of treatment in multiple sclerosis.
    Neurology. 2017;89:e265-e267.
    PubMed    


  395. DHAWAN PS, Dyck PJB, Tracy JA, Naddaf E, et al
    Systemic vasculitis with dermatomyositis, hearing loss, neuropathy, and multiorgan dysfunction.
    Neurology. 2017;89:2119-2120.
    PubMed    


  396. KOWALEC K, McKay KA, Patten SB, Fisk JD, et al
    Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004716.
    PubMed     Abstract available


  397. BURMAN J, Zelano J
    Epilepsy in multiple sclerosis: A nationwide population-based register study.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004740.
    PubMed     Abstract available


  398. HOUZEN H, Kondo K, Niino M, Horiuchi K, et al
    Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan.
    Neurology. 2017;89:1995-2001.
    PubMed     Abstract available


  399. ARRAMBIDE G, Tintore M, Auger C, Rio J, et al
    Lesion topographies in multiple sclerosis diagnosis: A reappraisal.
    Neurology. 2017 Nov 3. pii: 10.1212/WNL.0000000000004715.
    PubMed     Abstract available


  400. BARNETT C, Bril V, Kapral M, Kulkarni AV, et al
    Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency.
    Neurology. 2017 Nov 3. pii: 10.1212/WNL.0000000000004676.
    PubMed     Abstract available


    October 2017
  401. NOVAKOVA L, Zetterberg H, Sundstrom P, Axelsson M, et al
    Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Neurology. 2017 Oct 27. pii: 10.1212/WNL.0000000000004683.
    PubMed     Abstract available


  402. CHIANG S, Kesari NK, Bradshaw A, Chen W, et al
    Pearls & Oy-sters: CNS lymphoma in a patient with relapsing-remitting multiple sclerosis treated with interferon.
    Neurology. 2017;89:e210-e213.
    PubMed    


  403. MATHIS S, Magy L, Le Masson G, Vallat JM, et al
    Did Jules Dejerine describe AMAN at the end of the 19th century?
    Neurology. 2017;89:1749-1753.
    PubMed     Abstract available


  404. KARGIOTIS O, Safouris A, Petrou VN, Magoufis G, et al
    Teaching NeuroImages: Giant cell arteritis presenting with acute ischemic strokes due to diffuse intracranial stenoses.
    Neurology. 2017;89:e190-e191.
    PubMed    


  405. TSIVGOULIS G, Papadimitropoulos GN, Katsanos AH, Zompola C, et al
    Teaching NeuroImages: Interferon-induced psoriasis flare in a multiple sclerosis case remits with dimethyl fumarate.
    Neurology. 2017;89:e188-e189.
    PubMed    


  406. MUNGER KL, Hongell K, Aivo J, Soilu-Hanninen M, et al
    25-Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort.
    Neurology. 2017;89:1578-1583.
    PubMed     Abstract available


    September 2017
  407. LIEWLUCK T
    Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2017 Sep 27. pii: 10.1212/WNL.0000000000004610.
    PubMed    


  408. KARCESKI S
    Multiple sclerosis, inflammation in the brain, and mood.
    Neurology. 2017;89:e169-e171.
    PubMed    


  409. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1429-1430.
    PubMed    


  410. SETHI NK
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis and Physician-assisted death in chronic neurologic diseases.
    Neurology. 2017;89:1429.
    PubMed    


  411. MASDEU JC
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1428.
    PubMed    


  412. THORMANN A, Sorensen PS, Koch-Henriksen N, Laursen B, et al
    Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.
    Neurology. 2017 Sep 20. pii: 10.1212/WNL.0000000000004508.
    PubMed     Abstract available


  413. PLAVINA T, Muralidharan KK, Kuesters G, Mikol D, et al
    Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
    Neurology. 2017 Sep 15. pii: 10.1212/WNL.0000000000004485.
    PubMed     Abstract available


  414. MARRIE RA, Beck CA
    Preventing multiple sclerosis: To (take) vitamin D or not to (take) vitamin D?
    Neurology. 2017 Sep 13. pii: 10.1212/WNL.0000000000004506.
    PubMed    


  415. LOPEZ-CHIRIBOGA AS, Clardy SL
    Emerging Subspecialties in Neurology: Autoimmune neurology.
    Neurology. 2017;89:e129-e133.
    PubMed    


  416. FILLI L, Zorner B, Killeen T, Linnebank M, et al
    Author response: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1200.
    PubMed    


  417. DAVIS FA
    Letter re: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1199.
    PubMed    


  418. COLES AJ, Cohen JA, Fox EJ, Giovannoni G, et al
    Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Neurology. 2017;89:1117-1126.
    PubMed     Abstract available


  419. HAVRDOVA E, Arnold DL, Cohen JA, Hartung HP, et al
    Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
    Neurology. 2017;89:1107-1116.
    PubMed     Abstract available


  420. LORSCHEIDER J, Jokubaitis VG, Spelman T, Izquierdo G, et al
    Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
    Neurology. 2017;89:1050-1059.
    PubMed     Abstract available


    August 2017
  421. LANGER-GOULD A, Wu J, Lucas R, Smith J, et al
    Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study.
    Neurology. 2017 Aug 30. pii: 10.1212/WNL.0000000000004412.
    PubMed     Abstract available


  422. HENNES EM, Baumann M, Schanda K, Anlar B, et al
    Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.
    Neurology. 2017;89:900-908.
    PubMed     Abstract available


  423. ROSSI S, Studer V, Motta C, Polidoro S, et al
    Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004411.
    PubMed     Abstract available


  424. KOCH-HENRIKSEN N, Lauer K
    Dietary sodium intake: An etiologic dead end in multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004426.
    PubMed    


  425. CORTESE M, Yuan C, Chitnis T, Ascherio A, et al
    No association between dietary sodium intake and the risk of multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004417.
    PubMed     Abstract available


  426. WIENDL H, Bourdette D, Ciccarelli O
    Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?
    Neurology. 2017 Aug 23. pii: 10.1212/WNL.0000000000004381.
    PubMed    


  427. DE MEO E, Moiola L, Ghezzi A, Veggiotti P, et al
    MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004388.
    PubMed     Abstract available


  428. SUZUKI S, Ishikawa N, Konoeda F, Seki N, et al
    Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004359.
    PubMed     Abstract available


  429. BEECHER G, Anderson D, Siddiqi ZA
    Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial.
    Neurology. 2017 Aug 16. pii: 10.1212/WNL.0000000000004365.
    PubMed     Abstract available



  430. Escalation therapy for multiple sclerosis in Austria: Analysis of gender differences in the nationwide registry.
    Neurology. 2017;89:752.
    PubMed    


  431. HEHIR MK, Hobson-Webb LD, Benatar M, Barnett C, et al
    Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
    Neurology. 2017 Aug 11. pii: 10.1212/WNL.0000000000004341.
    PubMed     Abstract available


    July 2017
  432. NIELSEN NM, Munger KL, Stenager E, Ascherio A, et al
    Author response: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:411.
    PubMed    


  433. XIA Z, Cheng Q, Li J
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410-411.
    PubMed    


  434. ZARGHAMI A
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410.
    PubMed    


  435. MARANZANO J, Rudko DA, Nakamura K, Cook S, et al
    MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.
    Neurology. 2017 Jul 19. pii: 10.1212/WNL.0000000000004227.
    PubMed     Abstract available


  436. HACOHEN Y, Mankad K, Chong WK, Barkhof F, et al
    Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Neurology. 2017;89:269-278.
    PubMed     Abstract available


  437. LANGER-GOULD A, Smith JB, Hellwig K, Gonzales E, et al
    Breastfeeding, ovulatory years, and risk of multiple sclerosis.
    Neurology. 2017 Jul 12. pii: 10.1212/WNL.0000000000004207.
    PubMed     Abstract available



  438. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017;89:215.
    PubMed    


  439. URUHA A, Suzuki S, Nishino I
    Author update: Sarcoplasmic MxA expression: A valuable marker of dermatomyositis.
    Neurology. 2017;89:215.
    PubMed    


  440. BURKILL S, Montgomery S, Hajiebrahimi M, Hillert J, et al
    Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012.
    Neurology. 2017 Jul 7. pii: 10.1212/WNL.0000000000004216.
    PubMed     Abstract available


    June 2017
  441. LEWIS EJH, Perkins BA, Lovblom LE, Bazinet RP, et al
    Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial.
    Neurology. 2017;88:2294-2301.
    PubMed     Abstract available


  442. DE JONG HJI, Kingwell E, Shirani A, Cohen Tervaert JW, et al
    Evaluating the safety of beta-interferons in MS: A series of nested case-control studies.
    Neurology. 2017;88:2310-2320.
    PubMed     Abstract available


  443. BRENNA G, Antozzi C, Montomoli C, Baggi F, et al
    A propensity score analysis for comparison of T-3b and VATET in myasthenia gravis.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004082.
    PubMed     Abstract available


    May 2017
  444. BATISTA S, Alves C, d'Almeida OC, Afonso A, et al
    Disconnection as a mechanism for social cognition impairment in multiple sclerosis.
    Neurology. 2017 May 31. pii: 10.1212/WNL.0000000000004060.
    PubMed     Abstract available


  445. SOLOMON AJ, Weinshenker BG
    Author response: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067-2068.
    PubMed    


  446. DALLA COSTA G, Martinelli V, Comi G
    Letter re: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067.
    PubMed    


  447. ESHAGHI A, Ciccarelli O
    Author response: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed    


  448. AVASARALA J
    Letter re: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed    


  449. TIMMINGS PL, Siu R, Bukhari W, Todd A, et al
    Author response: Acute Zika infection with concurrent onset of Guillain-BarrE syndrome.
    Neurology. 2017;88:1874-1875.
    PubMed    


  450. GERARDIN P, Cao-Lormeau VM, Tournebize P, Cerny T, et al
    Letter re: Acute Zika infection with concurrent onset of Guillain-BarrE syndrome.
    Neurology. 2017;88:1874.
    PubMed    


  451. MEIJER KA, Eijlers AJC, Douw L, Uitdehaag BMJ, et al
    Increased connectivity of hub networks and cognitive impairment in multiple sclerosis.
    Neurology. 2017 May 3. pii: 10.1212/WNL.0000000000003982.
    PubMed     Abstract available


  452. AUBERT-BROCHE B, Weier K, Longoni G, Fonov VS, et al
    Monophasic demyelination reduces brain growth in children.
    Neurology. 2017;88:1744-1750.
    PubMed     Abstract available


  453. GAIG C, Graus F, Compta Y, Hogl B, et al
    Clinical manifestations of the anti-IgLON5 disease.
    Neurology. 2017;88:1736-1743.
    PubMed     Abstract available


    April 2017
  454. SORMANI MP, Muraro PA, Schiavetti I, Signori A, et al
    Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017 Apr 28. pii: 10.1212/WNL.0000000000003987.
    PubMed     Abstract available


  455. GIANFRANCESCO MA, Stridh P, Rhead B, Shao X, et al
    Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS.
    Neurology. 2017;88:1623-1629.
    PubMed     Abstract available


  456. NUNLEY KA, Leckie RL, Orchard TJ, Costacou T, et al
    Physical activity and hippocampal volume in middle-aged patients with type 1 diabetes.
    Neurology. 2017;88:1564-1570.
    PubMed     Abstract available


  457. MADDISON P, Gozzard P, Grainge MJ, Lang B, et al
    Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome.
    Neurology. 2017;88:1334-1339.
    PubMed     Abstract available


    March 2017
  458. LANDI D, De Rossi N, Zagaglia S, Scarpazza C, et al
    No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
    Neurology. 2017;88:1144-1152.
    PubMed     Abstract available


  459. ABSINTA M, Cortese IC, Vuolo L, Nair G, et al
    Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003820.
    PubMed     Abstract available


    February 2017
  460. NASH RA, Hutton GJ, Racke MK, Popat U, et al
    High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
    Neurology. 2017;88:842-852.
    PubMed     Abstract available


  461. KUHLE J, Nourbakhsh B, Grant D, Morant S, et al
    Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
    Neurology. 2017;88:826-831.
    PubMed     Abstract available


  462. MOWRY EM, McArthur JC
    PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
    Neurology. 2017 Feb 22. pii: 10.1212/WNL.0000000000003749.
    PubMed    


  463. MOLKO N, Simon O, Guyon D, Biron A, et al
    Zika virus infection and myasthenia gravis: Report of 2 cases.
    Neurology. 2017 Feb 10. pii: 10.1212/WNL.0000000000003697.
    PubMed    


  464. BARTON J, Hardy TA, Riminton S, Reddel SW, et al
    Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003694.
    PubMed    


  465. WYNN DP, Donigan JM, Tkach A
    Clinical Reasoning: A 74-year-old woman with bilateral foot pain and a palmar rash.
    Neurology. 2017;88:e44-e50.
    PubMed    


  466. BODINI B, Calabresi PA
    From neurofilament research to multiple sclerosis clinical practice: Where do we stand?
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003676.
    PubMed    


  467. BENNETT SE
    Fampridine: Long-term benefits in walking in multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003677.
    PubMed    


    January 2017
  468. SCHEIBE F, Pruss H, Mengel AM, Kohler S, et al
    Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis.
    Neurology. 2017;88:366-370.
    PubMed     Abstract available


  469. MAAROUF A, Audoin B, Pariollaud F, Gherib S, et al
    Increased total sodium concentration in gray matter better explains cognition than atrophy in MS.
    Neurology. 2017;88:289-295.
    PubMed     Abstract available


    December 2016
  470. ROCCA MA, Battaglini M, Benedict RH, De Stefano N, et al
    Brain MRI atrophy quantification in MS: From methods to clinical application.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003542.
    PubMed     Abstract available


  471. GOEDEE HS, van der Pol WL, van Asseldonk JH, Franssen H, et al
    Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies.
    Neurology. 2016 Dec 7. pii: 10.1212/WNL.0000000000003483.
    PubMed     Abstract available


    November 2016
  472. TENSER RB, Truini A, Cruccu G
    A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
    Neurology. 2016;87:2385-2386.
    PubMed    


  473. BEADNALL HN, Gill AJ, Riminton S, Barnett MH, et al
    Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003434.
    PubMed    


    October 2016
  474. BOURDETTE D
    Rituximab for treating multiple sclerosis: Off-label but on target.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003345.
    PubMed    


    September 2016
  475. KANTOR D, Sotirchos ES, Calabresi PA
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:1424.
    PubMed    


  476. KELLY DM, Kelleher EM, O'Shea A, Sweeney B, et al
    Teaching Video NeuroImages: Primary writing tremor: Lessons from a patient with multiple sclerosis.
    Neurology. 2016;87:e131.
    PubMed    


  477. ARNOLD DL, Fisher E, Brinar VV, Cohen JA, et al
    Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003169.
    PubMed     Abstract available


    July 2016
  478. SIU R, Bukhari W, Todd A, Gunn W, et al
    Acute Zika infection with concurrent onset of Guillain-Barre Syndrome.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003038.
    PubMed    


  479. BROWNLEE WJ, Swanton JK, Miszkiel KA, Miller DH, et al
    Should the symptomatic region be included in dissemination in space in MRI criteria for MS?
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002975.
    PubMed     Abstract available


  480. FERREIRA DA SILVA IR, Frontera JA, Moreira do Nascimento OJ
    News from the battlefront: Zika virus-associated Guillain-BarrE Syndrome in Brazil.
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000003024.
    PubMed    


    May 2016
  481. KOELMAN DL, Chahin S, Mar SS, Venkatesan A, et al
    Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study.
    Neurology. 2016;86:2085-93.
    PubMed     Abstract available


  482. HYUN JW, Jeong IH, Joung A, Kim SH, et al
    Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder.
    Neurology. 2016;86:1772-9.
    PubMed     Abstract available


  483. SPATOLA M, Du Pasquier R, Schluep M, Regeniter A, et al
    Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes.
    Neurology. 2016;86:1780-4.
    PubMed     Abstract available


  484. KASSAVETIS P, Joseph JB, Francois R, Perloff MD, et al
    Zika virus-associated Guillain-Barre syndrome variant in Haiti.
    Neurology. 2016 May 6. pii: 10.1212/WNL.0000000000002759.
    PubMed    


  485. VAN SONDEREN A, Schreurs MW, de Bruijn MA, Boukhrissi S, et al
    The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies.
    Neurology. 2016;86:1692-9.
    PubMed     Abstract available


  486. MELINYSHYN AN, Gofton TE, Schulz V
    Supernumerary phantom limbs in ICU patients with acute inflammatory demyelinating polyneuropathy.
    Neurology. 2016;86:1726-8.
    PubMed     Abstract available


    April 2016
  487. DE LOTT LB, Burke JF, Kerber KA, Skolarus LE, et al
    Medicare Part D payments for neurologist-prescribed drugs.
    Neurology. 2016;86:1491-8.
    PubMed     Abstract available


    March 2016
  488. HODEL J, Darchis C, Outteryck O, Verclytte S, et al
    Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Neurology. 2016 Mar 23. pii: 10.1212/WNL.0000000000002586.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: